Does medicare have an implicit cost-effectiveness threshold?

Medical Decision Making

Volumn 30, Issue 4, 2010, Pages

  Chambers, James D ^a,b   Neumann, Peter J ^b   Buxton, Martin J ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

cost effectiveness analysis; economic analysis; Medicare; pharmacoeconomics; resource allocation

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; MEDICARE; UNITED STATES;

COST-BENEFIT ANALYSIS; MEDICARE; UNITED STATES;

EID: 77954909367     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X10371134     Document Type: Article

References (87)

1. Notice: Medicare Program; Revised Process for Making Medicare National Coverage Determinations, Federal Register 68, no. 187 (26 September 2003); and GAO, Medicare: Divided Authority.
2. Centers for Medicare and Medicaid Services (CMS). National Coverage Determinations (NCDs). Available from: http://www.cms.hhs.gov/mcd/index-list. asp?list-type=ncd. Accessed 1 February 2008.
3. Centers for Medicare and Medicaid Services (CMS). Medicare Coverage Determination Process. Available from: http://www.cms.hhs.gov/ DeterminationProcess/
4. Neumann PJ Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. Oxford, UK: Oxford University Press; 2005.
5. The Boards of Trustees, Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. 2008 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. Available from: http://www.cms.hhs.gov/reportstrustfunds/ downloads/tr2008.pdf. Accessed 1 July 2008.
6. Guidance for the Public, Industry and CMS Staff. Factors CMS Considers in Opening a National Coverage Determination Document Issued: April 11, 2006. Available from: http://www.cms.hhs.gov/mcd/ncpc-view-document.asp?id=6. Accessed 1 February 2008.
7. Medicare Improvements for Patients and Providers Act (MIPPA), PL 110-275. 2008. Available from: www.govtrack.us/congress/billtext.xpd?bill=h110-6331. Accessed 1 July 2009.
8. Decision Memo for Screening Computed Tomography Colonography (CTC) for Colorectal Cancer (CAG-00396N). Available from: http://www.cms.hhs.gov/mcd/ viewdecisionmemo.asp?id=220. Accessed 1 July 2009.
9. Dhruva SS, Phurrough SE, Salive ME, Redberg RF CMS's landmark decision on CT colonography: examining the relevant data. N Engl J Med. 2009 ; 360: 2699-2701.
10. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision making: how are cost-effectiveness thresholds expected to emerge ? Value Health. 2004 ; 7: 518-528.
11. Gillick MR Medicare coverage for technological innovations: time for new criteria ? N Engl J Med. 2004 ; 350: 2199-2203.
12. PubMed, a service of the National Library of Medicine. Available from: http://www.ncbi.nlm.nih.gov/pubmed/. Accessed 1 February 2008.
13. Tufts Medical Center CEA Registry. Available from: www.cearegistry.org
14. Health Economics Evaluations Database (HEED). Available from: http://www.3.interscience.wiley.com/cgi-bin/mrwhome/114130635/HOME. Accessed 1 February 2008.
15. NHS Economic Evaluation Database. Available from: http://www.crd.york.ac. uk/crdweb/. Accessed 1 February 2008.
16. Organisation for Economic Co-operation and Development. Purchasing Power Parity (PPP) Statistics. Available from: http://www.oecd.org/dataoecd/61/56/ 39653523.xls
17. US Department of Labor, Bureau of Labor Statistics. Inflation Calculator. Available from: http://data.bls.gov/cgi-bin/cpicalc.pl. Accessed 1 February 2008.
18. Decision Memo for Screening Immunoassay Fecal-Occult Blood Test (CAG-00180N). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp? id=87
19. Decision Memo for Smoking & Tobacco Use Cessation Counseling (CAG-00241N). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp? id=130
20. Decision Memo for Magnetic Resonance Angiography of the Abdomen and Pelvis (CAG-00142N). Available from: http://www.cms.hhs.gov/mcd/ viewdecisionmemo.asp?id=51. Accessed 1 February 2008.
21. Decision Memo for External Counterpulsation (ECP) Therapy (CAG-00002R2). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=162. Accessed 1 February 2008.
22. Decision Memo for Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS) (CAG-00059N). Available from: http://www.cms.hhs.gov/mcd/ viewdecisionmemo.asp?id=22. Accessed 1 February 2008.
23. Decision Memo for Positron Emission Tomography (FDG) for Alzheimer's Disease/Dementia (CAG-00088N). Available from: http://www.cms.hhs.gov/mcd/ viewdecisionmemo.asp?id=64. Accessed 1 February 2008.
24. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3 rd ed. Oxford, UK: Oxford University Press ; 2005.
25. National Institute for Health and Clinical Excellence. Available from: http://www.nice.org.uk/. Accessed 1 February 2008.
26. Canadian Agency for Drugs and Technologies in Health. Available from: http://www.cadth.ca/index.php/en/home. Accessed 1 February 2008.
27. Medical Services Advisory Committee. Available from: http://www.msac.gov. au/. Accessed 1 February 2008.
28. Ramsey SD, Berry K., Etzioni R., et al. Cost-effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med. 2003 ; 348: 2092-2102.
29. Decision Memo for Lung Volume Reduction Surgery (LVRS) (CAG-00115R). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=96. Accessed 1 February 2008.
30. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006 ; 332: 699-703. 31. Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics. 2008 ; 26: 769-779.
31. Chapman RH, Berger M., Weinstein MC, Weeks JC, Goldie S., Neumann PJ When does quality-adjusting life-years matter in cost-effectiveness analysis ? Health Econ. 2004 ; 13: 429-436.
32. Keenan PS, Neumann PJ, Phillips KA Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Aff (Millwood). 2006 ; 25: 1260-1269.
33. Decision Memo for Ultrasound Stimulation for Nonunion Fracture Healing (CAG-00022R). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp? id=135. Accessed 1 February 2008.
34. Decision Memo for Insulin Infusion Pump (CAG-00041N). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=40. Accessed 1 February 2008.
35. Decision Memo for Ventricular Assist Devices as Destination Therapy-Chronic End-Stage Heart Failure Patients That Meet Specified Criteria (CAG-00119N). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp? id=79. Accessed 1 February 2008.
36. Decision Memo for Positron Emission Tomography (FDG) for Breast Cancer-Initial Staging of Axillary Lymph Nodes (CAG-00094N). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=71. Accessed 1 February 2008.
37. Decision Memo for Warm-Up Wound Therapy aka Noncontact Normothermic Wound Therapy NNWT Dominant (CAG-00114N). Available from: http://www.cms.hhs.gov/mcd/ viewdecisionmemo.asp?id=80. Accessed 1 February 2008.
38. Decision Memo for Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers-Ovarian cancer (CAG-00181N). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp? id=92. Accessed 1 February 2008.
39. Neumann PJ, Rosen AB, Weinstein MC Medicare and cost-effectiveness analysis. N Engl J Med. 2005 ; 353: 1516-1522.
40. Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff. 2000 ; 19: 92-109.
41. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation. Arch Intern Med. 2003 ; 163: 1637-1641.
42. Cutler DM, McClellan M. Is technological change in medicine worth it ? Health Aff. 2001 ; 20: 11-29.
43. Murray CJ, Evans DB, Acharya A., et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000 ; 9: 235-251.
44. Braithwaite RS, Meltzer DO, King JT, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule ? Med Care. 2008 ; 46: 349-356.
45. Benoit RM, Cohen JK, Miller RJ, et al. Comparison of the hospital costs for radical prostatectomy and cryosurgical ablation of the prostate. Urology. 1998 ; 52: 820-824.
46. Lee CH, Egglin TK, Philpotts L., et al. Cost-effectiveness of stereotactic core needle biopsy: analysis by means of mammographic findings. Radiology. 1997 ; 202: 849-854.
47. Liberman L., Feng TL, Dershaw DD, et al. US-guided core breast biopsy: use and cost-effectiveness. Radiology. 1998 ; 208: 717-723.
48. Ragnarson Tennvall G., Apelqvist J. Prevention of diabetes-related foot ulcers and amputations: a cost utility analysis based on Markov model simulations. Diabetologia. 2001 ; 44: 2077-2087.
49. Valk PE, Pounds TR, Tesar RD, et al. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996 ; 23: 737-743.
50. Miles KA An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography. Australas Radiol. 2001 ; 45: 9-18.
51. Aitken L., Addison C. The cost-effectiveness of ambulatory blood pressure monitoring. Prof Nurse. 1996 ; 12: 198-202.
52. Völler H., Dovifat C., Glatz J. Home management of anticoagulation. Eur Heart J Suppl. 2001 ; 3 (suppl Q). Q44-9.
53. Yu CM, Lau CP, Chau J., et al. A short course of cardiac rehabilitation program is highly cost effective in improving long-term quality of life in patients with recent myocardial infarction or percutaneous coronary intervention. Arch Phys Med Rehabil. 2004 ; 84: 1915-1922.
54. Sloka JS, Hollett PD, Mathews M. Cost-effectiveness of positron emission tomography in breast cancer. Mol Imaging Biol. 2005 ; 7: 351-360.
55. Daoud YJ, Amin KG Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol. 2006 ; 6: 600-606.
56. Levy MM, Baum RA, Carpenter JP Endovascular surgery based solely on noninvasive preprocedural imaging. J Vasc Surg. 1998 ; 28: 995-1003.
57. Siegrist PT, Husmann L., Knabenhans M., et al. (13)N-ammonia myocardial perfusion imaging with a PET/CT scanner: impact on clinical decision making and cost-effectiveness. Eur J Nucl Med Mol Imaging. 2008 ; 35: 889-895.
58. Report to the Agency for Healthcare Research and Quality: A Comparison of the Cost-Effectiveness of Fecal Occult Blood Tests with Different Test Characteristics in the Context of Annual Screening in the Medicare Population. Available from: http://www.cms.hhs.gov/coverage/download/id87.zip. Accessed 1 February 2008.
59. Hollenbeak CS, Lowe VJ, Stack BC The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer. 2001 ; 92: 2341-2348.
60. Ayas NT, FitzGerald JM, Fleetham JA, et al. Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. Arch Intern Med. 2006 ; 166: 977-984.
61. Guo S., Counte MA, Gillespie KN, et al. Cost-effectiveness of adjunctive hyperbaric oxygen in the treatment of diabetic ulcers. Int J Technol Assess Health Care. 2003 ; 19: 731-737.
62. Francis HW, Chee N., Yeagle J., et al. Impact of cochlear implants on the functional health status of older adults. Laryngoscope. 2002 ; 112 (pt 1). 1482-1488.
63. Clegg A., Colquitt J., Sidhu M., et al. Clinical and cost-effectiveness of surgery for morbid obesity: a systematic review and economic evaluation. Int J Obes Relat Metab Disord. 2003 ; 27: 1167-1177.
64. Martin SC, Gagnon DD, Zhang L., et al. Cost utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Pharmacoeconomics. 2003 ; 21: 1153-1169.
65. Mushlin AI, Hall WJ, Zwanziger J., et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Circulation. 1998 ; 97: 2129-2135.
66. Trippoli S., Messori A., Becagli P., et al. Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation. Oncol Rep. 1998 ; 5: 1475-1482. (Pubitemid 28474098)
67. Tomaszewski KJ, Holloway RG Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology. 2001 ; 57: 663-671.
68. Chan PS, Stein K., Chow T., et al. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-Eligible population. J Am Coll Cardiol. 2006 ; 48: 112-121.
69. Wallace MB, Nietert PJ, Earle C., et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/ laparoscopy. Ann Thorac Surg. 2002 ; 74: 1026-1032.
70. Larsen G., Hallstrom A., McAnulty J., et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation. 2002 ; 105: 2049-2057.
71. Sanders GD, Hlatky MA, Owens DK Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005 ; 353: 1471-1480.
72. Kiberd BA, Larson T. Estimating the benefits of solitary pancreas transplantation in nonuremic patients with type 1 diabetes mellitus: a theoretical analysis. Transplantation. 2000 ; 70: 1121-1127.
73. Low intensity ultrasound (TMUS) treatment for acceleration of bone fracture healing-Exogen bone growth stimulator. MSAC Application 1030, ISSN 1443-7120. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/ Content/MSAC%20Completed%20Assessments%201021%20-%201040. Accessed 1 February 2008.
74. Moore S., Tumeh J., Wojtanowski S., et al. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health. 2007 ; 10: 23-31.
75. Meads C., Salas C., Roberts T., et al. Clinical effectiveness and cost utility of photodynamic therapy for wet age-related macular degeneration-NHS R&D HTA Programme. Available from: http://www.nice.org.uk/nicemedia/pdf/ maculardegenerationassessmentreport.pdf. Accessed 1 February 2008.
76. Dan YY, Wai CT, Yeoh KG, et al. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl. 2006 ; 12: 736-746.
77. Campbell HE, Tait S., Buxton MJ, et al. A UK trial-based cost-utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris. Eur J Cardiothorac Surg. 2001 ; 20: 312-318.
78. Colquitt JL, Green C., Sidhu MK, et al. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess. 2004 ; 8: iii, 1-171.
79. Samson D. Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure. Chicago: Blue Cross and Blue Shield Association. Technology Evaluation Center Assessment Program Report. 2004 ; 19: 1-36.
80. Macario A., Dexter F. Is noncontact normothermic wound therapy cost effective for the treatment of stages 3 and 4 pressure ulcers ? Wounds. 2002 ; 14: 93-106.
81. Smith GT, Hubner KF, McDonald T., et al. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging. 1999 ; 2: 63-70.
82. Decision memo-Electrical Bioimpedance for Cardiac Output Monitoring (CAG-00001R2). Available from: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp? id=179. Accessed 1 February 2008.
83. Craig BM, Tseng DS Cost-effectiveness of gastric bypass for severe obesity. Am J Med. 2002 ; 113: 491-498.
84. Artificial intervertebral disc replacement (Total disc arthroplasty) MSAC application 1090, Assessment report, ISSN 1443-7120. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/ msac%20completed%20assessments%201081%20-%201100. Accessed 1 February 2008.
85. Reinhold T., Witt CM, Jena S., et al. Quality of life and cost-effectiveness of acupuncture treatment in patients with osteoarthritis pain. Eur J Health Econ. 2008 ; 9: 209-219.
86. Rauner MS, Heidenberger K., Pesendorfer EM Model-based evaluation of diabetic foot prevention strategies in Austria. Health Care Manag Sci. 2005 ; 8: 253-265.
87. Jordan WD, Roye GD, Fisher WS, et al. A cost comparison of balloon angioplasty and stenting versus endarterectomy for the treatment of carotid artery stenosis. J Vasc Surg. 1998 ; 27: 16-22.